Amanda Kaufmann1, Brian Hitsman2, Patricia M Goelz1, Anna Veluz-Wilkins2, Sonja Blazekovic1, Lindsay Powers2, Frank T Leone3, Peter Gariti1, Rachel F Tyndale4, Robert A Schnoll5. 1. Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA 19104. 2. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 N Lakeshore Drive, Chicago, IL 60611. 3. Pulmonary, Allergy, & Critical Care Division, University of Pennsylvania Presbyterian Medical Center, 51 N. 39th Street, Philadelphia, PA 19104. 4. Centre for Addiction and Mental Health, 1 King's College Circle, University of Toronto, Toronto, Ontario, Canada, M5S 1A6; Department of Pharmacology & Toxicology, 1 King's College Circle, University of Toronto, Toronto, Ontario, Canada, M5S 1A6; Department of Psychiatry, 1 King's College Circle, University of Toronto, Toronto, Ontario, Canada, M5S 1A6. 5. Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA 19104. Electronic address: schnoll@mail.med.upenn.edu.
Abstract
BACKGROUND: In samples from controlled randomized clinical trials, a smoker's rate of nicotine metabolism, measured by the 3-hydroxycotinine to cotinine ratio (NMR), predicts response to transdermal nicotine. Replication of this relationship in community-based samples of treatment-seeking smokers may help guide the implementation of the NMR for personalized treatment for nicotine dependence. METHODS: Data from a community-based sample of treatment seeking smokers (N=499) who received 8weeks of transdermal nicotine and 4 behavioral counseling sessions were used to evaluate associations between the NMR and smoking cessation. Secondary outcomes included withdrawal and craving, depression and anxiety, side effects, and treatment adherence. RESULTS: The NMR was a significant predictor of abstinence (OR=.56, 95% CI: 0.33-0.95, p=.03), with faster metabolizers showing lower quit rates than slower metabolizers (24% vs. 33%). Faster nicotine metabolizers exhibited significantly higher levels of anxiety symptoms over time during treatment, vs. slower metabolizers (NMR x Time interaction: F[3,357]=3.29, p=.02). NMR was not associated with changes in withdrawal, craving, depression, side effects, and treatment adherence (p's>.05). CONCLUSIONS: In a community-based sample of treatment-seeking smokers, faster nicotine metabolizers were significantly less likely to quit smoking and showed higher rates of anxiety symptoms during a smoking cessation treatment program, vs. slower nicotine metabolizers. These results provide further evidence that transdermal nicotine is less effective for faster nicotine metabolizers and suggest the need to address cessation-induced anxiety symptoms among these smokers to increase the chances for successful smoking cessation.
BACKGROUND: In samples from controlled randomized clinical trials, a smoker's rate of nicotine metabolism, measured by the 3-hydroxycotinine to cotinine ratio (NMR), predicts response to transdermal nicotine. Replication of this relationship in community-based samples of treatment-seeking smokers may help guide the implementation of the NMR for personalized treatment for nicotine dependence. METHODS: Data from a community-based sample of treatment seeking smokers (N=499) who received 8weeks of transdermal nicotine and 4 behavioral counseling sessions were used to evaluate associations between the NMR and smoking cessation. Secondary outcomes included withdrawal and craving, depression and anxiety, side effects, and treatment adherence. RESULTS: The NMR was a significant predictor of abstinence (OR=.56, 95% CI: 0.33-0.95, p=.03), with faster metabolizers showing lower quit rates than slower metabolizers (24% vs. 33%). Faster nicotine metabolizers exhibited significantly higher levels of anxiety symptoms over time during treatment, vs. slower metabolizers (NMR x Time interaction: F[3,357]=3.29, p=.02). NMR was not associated with changes in withdrawal, craving, depression, side effects, and treatment adherence (p's>.05). CONCLUSIONS: In a community-based sample of treatment-seeking smokers, faster nicotine metabolizers were significantly less likely to quit smoking and showed higher rates of anxiety symptoms during a smoking cessation treatment program, vs. slower nicotine metabolizers. These results provide further evidence that transdermal nicotine is less effective for faster nicotine metabolizers and suggest the need to address cessation-induced anxiety symptoms among these smokers to increase the chances for successful smoking cessation.
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: Sandra Baker Morissette; Matthew T Tull; Suzy Bird Gulliver; Barbara Wolfsdorf Kamholz; Rose T Zimering Journal: Psychol Bull Date: 2007-03 Impact factor: 17.737
Authors: M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale Journal: Clin Pharmacol Ther Date: 2009-03-11 Impact factor: 6.875
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Laura MacPherson; Matthew T Tull; Alexis K Matusiewicz; Samantha Rodman; David R Strong; Christopher W Kahler; Derek R Hopko; Michael J Zvolensky; Richard A Brown; C W Lejuez Journal: J Consult Clin Psychol Date: 2010-02
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael F Fleming; Amy A Bittrich; Jennifer L Brown; Cathlyn J Leitzke; Mark E Zehner; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2010-02
Authors: Michael J Zvolensky; Sherry H Stewart; Anka A Vujanovic; Dubravka Gavric; Dan Steeves Journal: Nicotine Tob Res Date: 2009-02-23 Impact factor: 4.244
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Natalie Nardone; Marian Shahid; Andrew A Strasser; Delia A Dempsey; Neal L Benowitz Journal: Pharmacol Biochem Behav Date: 2019-12-05 Impact factor: 3.533
Authors: Nancy C Jao; Anna K Veluz-Wilkins; Matthew J Smith; Allison J Carroll; Sonja Blazekovic; Frank T Leone; Rachel F Tyndale; Robert A Schnoll; Brian Hitsman Journal: Exp Clin Psychopharmacol Date: 2017-06 Impact factor: 3.157
Authors: Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman Journal: Addiction Date: 2017-04-21 Impact factor: 6.526
Authors: Natalie Nardone; Eric C Donny; Dorothy K Hatsukami; Joseph S Koopmeiners; Sharon E Murphy; Andrew A Strasser; Jennifer W Tidey; Ryan Vandrey; Neal L Benowitz Journal: Addiction Date: 2016-08-01 Impact factor: 6.526
Authors: Terril L Verplaetse; MacKenzie R Peltier; Walter Roberts; Kelly E Moore; Brian P Pittman; Sherry A McKee Journal: Nicotine Tob Res Date: 2020-07-16 Impact factor: 4.244